stockportfolio.pro
Charming Medical Limited (MCTA)
Healthcare · Medical Care Facilities · NasdaqCM
Charming Medical Limited revenue & earnings — last 3 fiscal years
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $3.53M | $6.02M | $6.22M |
| Gross profit | $1.49M | $3.91M | $4.18M |
| Net income | $-305,117 | $777,811 | $1.20M |
| Net margin | -8.6% | 12.9% | 19.3% |
Source: Charming Medical Limited SEC filings (10-K).
What growth is priced into MCTA stock?
At today's market cap of $504.26M, Charming Medical Limited is priced for free-cash-flow growth of about 89.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $138,361 from the FY ending 2025-03-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 3 years of Charming Medical Limited financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MCTA in your portfolio →
Charming Medical Limited financial history by metric
About Charming Medical Limited
Charming Medical Limited, through its subsidiaries, engage in the provision of beauty, wellness, and postpartum services under the Beauty Lab brand name in Hong Kong. Its services includes womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox therapy, agarwood moxibustion therapy, traditional Chinese medicine (TCM)-inspired prenatal massage, and Indonesian traditional abdominal binding. The company also provides TCM-inspired supplements products, which includes Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets; and beauty products, including ginseng soothing anti-allergy moisturizing wash for skin issues, and scalp health. In addition, it offers consultancy services to provide TCM-inspired therapy technical training and dietary therapy training to other well-established and reputable beauty salons, massage centers, and similar institutions. Further, the company's products are used for the treatment of alleviating premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal care, breast health, uterine health, enhance physical weakness, balance endocrine functions, and other common women's health issues. it operates wellness centres. The company was founded in 2016 and is headquartered in Causeway Bay, Hong Kong.
Charming Medical Limited — frequently asked questions
What is Charming Medical Limited's revenue?
Charming Medical Limited (MCTA) reported revenue of $6.22M for fiscal year 2025, up 3.4% from the prior year, according to its SEC filings.
Is Charming Medical Limited profitable?
Yes. MCTA earned net income of $1.20M in fiscal 2025, a net margin of 19.3%.
What is MCTA's P/E ratio?
Charming Medical Limited trades at a price-to-earnings ratio of about 419.4 based on the latest data in our nightly-refreshed cache.
How fast is Charming Medical Limited growing?
MCTA's revenue grew at roughly 32.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Charming Medical Limited have?
As of fiscal year 2025, MCTA carried roughly $314,226 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Charming Medical Limited's gross margin?
MCTA's gross margin was 67.2% in fiscal 2025 — gross profit of $4.18M on revenue of $6.22M.
What is Charming Medical Limited's market cap?
Charming Medical Limited (MCTA) has a market capitalization of about $504.26M, based on the latest data in our nightly-refreshed cache.
When does Charming Medical Limited's fiscal year end?
MCTA's fiscal year ends in March. Its most recent annual filing covers the fiscal year ending 2025-03-31.
What growth is priced into MCTA stock?
At today's market cap of $504.26M, Charming Medical Limited is priced for free-cash-flow growth of about 89.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $138,361 from the FY ending 2025-03-31).
Where does this data come from?
All figures are computed from Charming Medical Limited's official SEC filings (10-K and 10-Q), covering 3 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.